At University of California San Diego (UC San Diego), in order to continue to offer our students the experience of being and learning on a college campus in the midst of the global pandemic, a team of our university clinicians, molecular biologist, technologists, infectious disease experts, bioinformatics specialists, disease modelers, public health experts and others launched a new program called Return to Learn, back in May 2020.
The Return to Learn program is an adaptive model which includes “Risk Mitigation,” “Viral Detection,” and “Intervention” and has protected student, employee, and public health and safety. UC San Diego has managed to maintain 25% density for faculty and staff, as allowed by State and County guidelines, and enabled nearly 10,000 students to be and learn on campus.
Given the current rapid increase in coronavirus case and death numbers in Japan, LINK-J is pleased to offer a timely special webinar about the COVID-19 responses at UC San Diego inviting Dr. Robert T. “Chip” Schooley, Professor of Medicine, Division of Infectious Diseases and Global Public Health, who has played a key role as an infectious disease expert to steer the informed decision-making process of the Return to Learn program. Dr. Schooley will share the precious lessons he and his colleagues have learned in implementing this program to keep the campus safe for students and employees against the constantly changing phases of this terrible pandemic in the broader communities.
The UC San Diego Return to Learn program represents higher education at its finest, and if successful, it can help this university and similar institutions to do what we do best: teach, conduct leading-edge research and provide service to our communities. We hope the special webinar will inspire those who are responsible for CODIV-19 responses in various sectors concerned in Japan.
*Language:English (English-Japanese simultaneous interpretation available)
*English captions are available (you can choose to turn them on or off).
*Please note that LINK-J and UC San Diego are not responsible for any errors or omissions in the captions.
How to use captions: Managing and viewing closed captioning
Date and Time:
February 2, 2021 at 5:00-6:00 PM（Pacific Time）/ February 3, 2021 at 10:00-11:00 AM (Japan time)
Online (Zoom Webinar)
(Opens an external site)
|FEB 3 (JST)||FEB 2 (PST)||AGENDA|
|10:00-10:05 AM||5:00-5:05 PM||Remarks by Akihiko Soyama (LINK-J) and Miwako Waga (UC San Diego)|
|10:05-10:40 AM||5:05-5:40 PM||Robert T. “Chip” Schooley, M.D. “COVID-19 Responses at UC San Diego – Sharing Lessons We’ve Learned from Our ‘Return to Learn’ Program”|
|10:40-10:58 AM||5:40-5:58 PM||Q&A and Discussion – moderated by Miwako Waga|
|10:58-11:00 AM||5:58-6:00 PM||Closing Remarks – Akihiko Soyama, LINK-J|
|11:00-11:10 AM||6:00-6:10 PM||Overrun (if there are many questions)|
Click ”Registration” to open an external site, and click “GET TICKET” on the right bar to sign up for the webinar.
Robert T. "Chip" Schooley, M.D.
Professor of Medicine, Division of Infectious Diseases and Global Public Health
Co-Director, Center for Innovative Phage Applications and Therapeutics
Senior Director, International Initiatives
Interim Faculty Director, Global Education
Dr. Schooley is a graduate of the Johns Hopkins University School of Medicine. He completed an internal medicine residency at the Johns Hopkins Hospital and infectious disease fellowships at the National Institute of Allergy and Infectious Diseases and the Massachusetts General Hospital. He joined the faculty of Harvard Medical School in 1981 and shifted his research focus from herpesgroup viruses as recognition of the AIDS epidemic developed. Dr. Schooley was then recruited to the University of Colorado in 1990 as Head of the Division of Infectious Diseases where he developed an integrated HIV program clinical care and research program. He was elected Chair of the NIH’s AIDS Clinical Trials Group (ACTG) in 1995 and led that group until 2002 during which time the ACTG performed many of the seminal studies that defined modern antiretroviral chemotherapy. Dr. Schooley led the ACTG in its expansion from a domestic US research operation into one with a global reach with research units in Africa, India, Thailand, Haiti and Latin America. In 2005, he joined the faculty at the University of California San Diego where he served as Head of the Division of Infectious Diseases until 2017. He also serves as Editor-in-Chief of Clinical Infectious Diseases. His research interests are in the diagnosis, pathogenesis and therapy of viral infections and in global health.
Host : LINK-J, Co-Host : UC San Diego